A landmark randomized controlled trial published in Nature Medicine reveals that pramipexole, a dopamine agonist traditionally used for Parkinson’s disease, significantly alleviates anhedonia in patients with major depressive disorder, dysthymia, and bipolar depression. This finding represents a meaningful shift in depression treatment strategy, moving beyond conventional serotonin-focused approaches to target the dopamine pathways underlying reward processing and motivation. Anhedonia—the inability to experience pleasure from previously enjoyed activities—affects approximately 75 percent of depression patients and frequently persists despite adequate treatment with standard antidepressants. The trial’s positive results suggest pramipexole may offer clinicians a valuable tool for addressing this debilitating symptom, particularly in treatment-resistant cases where traditional interventions have proven insufficient. These findings open new therapeutic avenues for improving quality of life and functional outcomes in depressed populations. Read the full article on GMJ Newsroom.
Was this article helpful?
